HEALTHFINANCIAL TIMES WORLD
Eli Lilly and Bayer hit out at Germany’s spending on new medicines
Eli Lilly and Bayer criticize Germany's spending on new medicines. Pharmaceutical groups support the US's opposition to legislation aimed at lowering drug prices.
Related Signal
Adjacent reporting
- STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
- Campaigners threaten legal action over UK-US deal on prices NHS pays for drugs
- Dozens of MPs oppose Streeting’s new power to say what NHS pays for drugs
- STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices